Skip to main content
    A

    Actinium Pharmaceuticals Inc (ATNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.49
    -0.15 (-9.45%)

    Market Cap: $51.56M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Actinium Pharmaceuticals Inc (ATNM) Financials: Revenue, Profit and Cash Flow

    Updated Aug 7, 2026. Financial statements from company filings, amounts in US dollars.

    Actinium Pharmaceuticals reported revenue of $90.00K for the fiscal year ended Dec 31, 2025. That year, net income was -$33.89M with a net margin of -37652.2%, operating cash flow was -$24.58M and free cash flow was -$24.68M. The quarter ended Jun 30, 2026 had revenue of $35.00M and net income of $27.90M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$90.00KN/A100.0%-40274.4%-37652.2%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$81.00K-92.1%100.0%-64098.8%-60269.1%
    Dec 2022$1.03M-55.0%100.0%-3311.1%-3205.5%
    Dec 2021$2.29MN/A100.0%-1091.1%-1082.8%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$90.00K$0$81.00K$1.03M$2.29M$0$0$0$0$0
    Gross profit$90.00K$0$81.00K$1.03M$2.29M$0$0$0$0$0
    Research and development$21.12M$30.05M$38.67M$23.14M$18.03M$16.09M$16.55M$17.09M$17.72M$17.83M
    Operating income-$36.25M-$42.12M-$51.92M-$34.10M-$24.96M-$22.39M-$22.07M-$23.83M-$26.91M-$26.85M
    Net income-$33.89M-$38.24M-$48.82M-$33.02M-$24.77M-$22.21M-$21.90M-$23.65M-$26.60M-$24.32M
    EBITDA-$35.43M-$41.31M-$51.13M-$33.41M-$24.44M-$21.95M-$21.48M-$23.78M-$26.55M-$24.24M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$35.00M$0$0$90.00K$0$0$810.00K$0$0$0$81.00K$0
    Gross profit$35.00M$0$615.00K$90.00K$0$0-$204.00K$0$0$0$81.00K$0
    Operating income$27.57M-$5.90M-$6.41M-$5.69M-$7.50M-$16.64M-$7.50M-$12.60M-$12.42M-$9.60M-$10.34M-$14.35M
    Net income$27.90M-$5.52M-$5.94M-$5.13M-$6.88M-$15.94M-$6.65M-$11.57M-$11.35M-$8.67M-$9.32M-$13.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $722.00K by $47.28M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$51.77M$76.90M$81.44M$114.19M$80.39M$66.40M$11.67M$14.89M$18.34M$22.53M
    Current assets$49.38M$74.51M$78.26M$110.94M$79.75M$64.92M$10.09M$14.33M$17.84M$22.39M
    Cash and equivalents$48.00M$72.90M$76.68M$108.91M$77.83M$63.56M$9.25M$13.67M$17.40M$20.52M
    Total liabilities$43.94M$44.14M$45.07M$47.71M$6.84M$5.08M$6.03M$6.08M$4.67M$4.52M
    Short-term debt$722.00K$580.00K$541.00K$10.13M$307.00K$4.34M$381.00K$249.24K$0$300.68K
    Shareholder equity$7.83M$32.76M$36.38M$66.48M$73.55M$61.32M$5.64M$8.81M$13.67M$18.01M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$40.16M$45.44M$51.77M$56.15M$63.02M$68.65M$76.90M$82.11M$89.86M$88.35M$81.44M$88.94M
    Total liabilities$9.86M$43.13M$43.94M$42.37M$44.00M$42.95M$44.14M$43.91M$46.03M$44.49M$45.07M$45.36M
    Cash and equivalents$36.47M$42.13M$48.00M$53.39M$59.93M$65.33M$72.90M$78.66M$86.04M$84.06M$76.68M$82.98M
    Shareholder equity$30.30M$2.30M$7.83M$13.78M$19.01M$25.69M$32.76M$38.21M$43.84M$43.86M$36.38M$43.58M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$24.58M-$33.07M-$47.34M$8.64M-$20.87M-$21.62M-$21.46M-$20.57M-$21.55M-$20.79M
    Capital expenditures$104.00K$11.00K$153.00K$366.00K$133.00K$253.00K$64.00K$96.09K$24.74K$59.96K
    Free cash flow-$24.68M-$33.08M-$47.49M$8.28M-$21.00M-$21.87M-$21.53M-$20.67M-$21.58M-$20.85M
    Dividends paidN/AN/AN/AN/AN/A$1.00K$1.27KN/AN/AN/A
    Investing cash flow-$104.00K-$11.00K-$153.00K-$366.00K-$133.00K-$253.00K-$64.00K-$96.09K-$24.74K-$109.82K
    Financing cash flow-$217.00K$29.32M$14.87M$23.11M$35.22M$76.18M$17.11M$16.98M$18.81M$15.78M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$5.18M-$5.87M-$5.29M-$6.33M-$5.39M-$7.57M-$5.75M-$11.97M-$7.97M-$7.37M-$7.49M-$11.13M
    Capital expenditures$478.00K$2.00K$104.00K$0$0$0$0$0$0$11.00K$0$30.00K
    Free cash flow-$5.66M-$5.87M-$5.39M-$6.33M-$5.39M-$7.57M-$5.75M-$11.97M-$7.97M-$7.38M-$7.49M-$11.15M
    Last 12 quarters

    Frequently Asked Questions About ATNM

    What is Actinium Pharmaceuticals' annual revenue?

    Actinium Pharmaceuticals reported revenue of $90.00K for the fiscal year ended Dec 31, 2025.

    Is Actinium Pharmaceuticals profitable?

    No. Actinium Pharmaceuticals reported net income of -$33.89M for the fiscal year ended Dec 31, 2025, with a net margin of -37652.2%.

    How much free cash flow does ATNM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.58M minus capital expenditures of $104.00K produced free cash flow of -$24.68M.

    How much debt does Actinium Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $722.00K and cash and equivalents of $48.00M.

    What is ATNM's profit margin?

    For the fiscal year ended Dec 31, 2025, Actinium Pharmaceuticals reported gross margin of 100.0%, operating margin of -40274.4% and net margin of -37652.2%.